Bilateral ballism induced by ibuprofen in a schizophrenic patient Sir, Administration of non-steroidal anti-inflammatory drugs (NSAID) has been rarely reported to produce involuntary movement disorders.' 2 3 We report a 68 year old woman with a 30-year history of paranoid-hallucinatory schizophrenia (Type 1 syndrome)4 in whom administration of ibuprofen produced acute bilateral ballistic movements.
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The patient had been on a neuroleptic (trifluoroperazine hydrochloride, 6mg/day) for 10 years. Approximately 3 years ago she developed neuroleptic-induced tardive dyskinesia. Trifluoroperazine was discontinued and she was placed on benztropine mesylate (3 mg/day) which was ineffective in controlling the involuntary dyskinetic movements. Approximately 6 weeks before our evaluation she was placed on ibuprofen (1800mg/day) for osteoarthritic pain. Within 24 hours the patient noticed a marked exacerbation of the orofacial dyskinesia and shortly thereafter developed ballistic movements characterized by violent flinging of both arms and head that persisted during sleep. These ballistic movements as well as the oro-facial involuntary dyskinesias persisted for one week after which they gradually diminished in severity over 72 hours following discontinuation of the drug. On recent evaluation the patient disclosed the typical symptoms of tardive dyskinesia associated with akathisia.
The temporal association between the development of the ballistic movements with initiation of ibuprofen therapy and cessation of the movements upon withdrawal of the drug implicates ibuprofen as the causative agent. There was no family history of involuntary movements and laboratory investigations proved normal.
Administration of NSAID has been reported to produce dyskinetic movements' 2 and exacerbate parkinsonism3 as well as ameliorate parkinsonian symptoms,5 suggesting that these agents may exert both dopaminergic and antidopaminergic effects on striatal neurones. In addition, prostaglandin inhibitors have been reported to augment central and peripheral adrenaline turnover in the rat.6 '
The current neurochemical concept of tardive dyskinesia implicates post-synaptic dopamine receptor supersensitivity in the pathophysiology of the disorder. 
